COMMUNIQUÉS West-GlobeNewswire

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14/07/2026
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential [...]
Aeroflow Sleep Donates to Beds for Kids and Project Sleep to Improve Sleep Health Equity
14/07/2026
Both donations reinforce Aeroflow Sleep’s commitment to closing gaps in healthcare access and promoting healthy sleep for all ASHEVILLE, N.C., July 14, 2026 (GLOBE NEWSWIRE) -- Aeroflow Sleep , a nationwide provider of [...]
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia
14/07/2026
Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo. The LiBBY study [...]
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
14/07/2026
WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension [...]
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
14/07/2026
CEO discusses ERNA-101's potential to transform immunologically "cold" tumors into tumors the immune system can recognize and kill Video highlights compelling preclinical data, differentiated off-the-shelf iMSC platform [...]
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
14/07/2026
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering IRVINE, Calif., July 14, 2026 ( [...]
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
14/07/2026
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeningeal metastases, including CSF cytology follow-up every 4 to 8 weeks for patients receiving intrathecal therapy, to [...]
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term [...]
Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor
14/07/2026
SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new [...]
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
14/07/2026
Through a series of investments over the past year, including an additional investment made in June 2026, Weinstein has built an ownership position of more than 30% as Pluri advances its longevity and U.S. [...]
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
14/07/2026
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14 [...]
XOMA Royalty Announces Closing of Its Acquisition by Ligand
14/07/2026
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty. [...]
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]
Transactions in connection with share buy-back program
14/07/2026
Company announcement no. 25 - 26 14 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards
14/07/2026
From 647 applications worldwide, Hummingbird Bioscience was selected by an independent judging panel as a winner at the AI Discovery Awards hosted by Nebius The awards program spotlights companies leveraging AI to [...]
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
14/07/2026
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics OXFORD, United Kingdom, July 14, 2026 (GLOBE NEWSWIRE) -- [...]
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy
14/07/2026
Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once [...]
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and [...]

Pages